Home Newsfeeds Oppenheimer Downgrades CinCor Pharma to Perform

Oppenheimer Downgrades CinCor Pharma to Perform

Oppenheimer analyst Jay Olson downgrades CinCor Pharma (NASDAQ:CINC) from Outperform to Perform.

byBenzinga Newsdesk

November 29, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades CinCor Pharma (NASDAQ:CINC) from Outperform to Perform.

AG Mortgage Investment Trust Announces Series Of Corporate Governance Changes; T.J. Durkin As The Company’s CEO Effective October 1, Continue As President Of Board; David Roberts Will Resign As The Company’s Chairman And CEO

By Benzinga Newsdesk

September 22, 4:30 PM

T.J. Durkin, President of MITT, to Assume Role of Chief Executive Officer of MITT Lead Independent Director Debra Hess to Become Non-Executive Chair of MITT's Board of Directors Nicholas Smith, Chief Investment

MITT

Wells Fargo Likely To Report Surge In Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

By Avi Kapoor

January 11, 11:33 AM

Wells Fargo & Company (NYSE: WFC) is projected to release financial results for its fourth quarter, before the opening bell on Jan. 12, 2024.

WFC

Installed Building Prods Q3 Adj. EPS $2.51 Beats $2.30 Estimate, Sales $719.11M Beat $671.15M Estimate

By Benzinga Newsdesk

November 3, 7:13 AM

Installed Building Prods (NYSE:IBP) reported quarterly earnings of $2.51 per share which beat the analyst consensus estimate of $2.30 by 9.13 percent. This is a 68.46 percent increase over earnings of $1.49 per share

IBP